(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.